

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Kathiresan Sekar</u> (Last) (First) (Middle) C/O VERVE THERAPEUTICS 500 TECHNOLOGY SQUARE, SUITE 901 (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Verve Therapeutics, Inc. [VERV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Executive Officer
	3. Date of Earliest Transaction (Month/Day/Year) 07/07/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/07/2022		G	V	160,000 ⁽¹⁾	D	\$0.00	317,839 ⁽²⁾	D	
Common Stock	07/07/2022		G	V	160,000 ⁽¹⁾	A	\$0.00	240,997 ⁽¹⁾	I	Kathiresan Family 2021 Irrevocable Trust
Common Stock								80,997	I	Sekar Kathiresan 2021 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$8.24	07/12/2022		G ⁽³⁾	V		140,000	(4)	02/11/2031	Common Stock	140,000	\$0.00	291,988	D	
Stock Option (right to buy)	\$2.87	07/12/2022		G ⁽⁵⁾	V		160,000	(6)	09/15/2030	Common Stock	160,000	\$0.00	445,308	D	
Stock Option (right to buy)	\$8.24	07/12/2022		G	V	140,000		(7)	02/11/2031	Common Stock	140,000	\$0.00	140,000 ⁽³⁾	I	Sekar Kathiresan 2022 Annuity Trust
Stock Option (right to buy)	\$2.87	07/12/2022		G	V	160,000		(7)	09/15/2030	Common Stock	160,000	\$0.00	300,000 ⁽⁵⁾	I	Sekar Kathiresan 2022 Annuity Trust

Explanation of Responses:

- On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.
- Includes 314 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
- On July 12, 2022, the reporting person transferred an employee stock option to purchase 140,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.
- The remaining shares underlying this option, which was granted on February 12, 2021, vest in equal monthly installments until February 1, 2025.
- On July 12, 2022, the reporting person transferred an employee stock option to purchase 160,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.
- The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
- The shares underlying the option being transferred were fully vested as of the date of transfer.

Remarks:

/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan 07/15/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.